Literature DB >> 19447310

Electrolyte complications of malignancy.

Robert F Kacprowicz1, Jeremy D Lloyd.   

Abstract

A thorough working knowledge of the diagnosis and treatment of life-threatening electrolyte abnormalities in cancer patients, especially hyponatremia, hypoglycemia, and hypercalcemia, is essential to the successful practice of emergency medicine. Although most minor abnormalities have no specific treatment, severe clinical manifestations of several notable electrolytes occur with significant frequency in the setting of malignancy. The treatment of life-threatening electrolyte abnormalities is reviewed here. Promising future treatments directed at the underlying physiology are also introduced.

Entities:  

Mesh:

Year:  2009        PMID: 19447310     DOI: 10.1016/j.emc.2009.01.007

Source DB:  PubMed          Journal:  Emerg Med Clin North Am        ISSN: 0733-8627            Impact factor:   2.264


  4 in total

Review 1.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

2.  Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma.

Authors:  A N Jeppesen; H K Jensen; F Donskov; N Marcussen; H von der Maase
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

3.  Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.

Authors:  Junya Furukawa; Hideaki Miyake; Yuji Kusuda; Masato Fujisawa
Journal:  Int J Clin Oncol       Date:  2014-06-04       Impact factor: 3.402

4.  Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors.

Authors:  Giandomenico Roviello; Martina Catalano; Ugo De Giorgi; Marco Maruzzo; Sebastiano Buti; Elisabetta Gambale; Giuseppe Procopio; Carlotta Ottanelli; Enrico Caliman; Luca Isella; Pierangela Sepe; Nicole Brighi; Matteo Santoni; Luca Galli; Raffaele Conca; Laura Doni; Lorenzo Antonuzzo
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.